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Secretogranin II (SgII) belongs to the family of chrom-
ogranins, which are widely expressed in large dense-core
vesicles (LDV) of nerves and neuroendocrine tissues. In
LDV SgII is processed to smaller peptides, like secretone-
urin (SN). SN was initially described in our lab [1] and
has been established as a novel biologically active neu-
ropeptide linking nerves, blood vessels and the immune
system. SN releases dopamine and dynorphin from rat
striatal slices, potently and specifically attracts monocytes,
eosinophils, dendritic and endothelial cells towards a
concentration gradient and acts as an angiogenic and vas-
culogenic cytokine comparable in potency to VEGF. SN
contributes to neurogenic inflammation and might play a
role in the irritative response in the eye, as it innervates a
wide range of ocular tissues. The role of SN in hypoxia-
driven induction of neo-vascularization in ischemic dis-
eases like cerebral ischemia or in solid tumours will be
subject of studies with a conditional knockout mouse for
the secretogranin II gene. For these studies, a targeting vec-
tor was generated in our lab. In classical knockout animals
the target gene is disrupted by either deleting parts of the
gene, or by insertion of foreign DNA sequences into the
target gene by site-specific homologous recombination.
This genetic rearrangement is present in each cell of the
animal right from the start. In conditional knockout ani-
mals, the structure and function of the gene of interest is
only minimally altered. The gene of interest gets flanked
by loxP sites, which serve as cleavage site for the Cre
recombinase. In the presence of this enzyme, the gene will
be excised precisely while other cells without Cre recom-
binase remain unaffected. The advantages of the condi-
tional knockout system are: (i) It circumvents problems of
simple knockouts such as compensation during develop-
ment. (ii) Spatial knockout allows the study of gene func-
tions in defined regions or tissues, without complications
due to whole-body gene deletion. The generation of a con-
ditional SgII knockout mouse will contribute to a better
understanding of the physiological relevance of SN. Alter-
ations of these mice in physiological and pathological
conditions central to angiogenesis like wound healing; tis-
sue ischemia following cardiovascular diseases; tumour
growth and metastasis will be investigated. Due to the
involvement of chromogranins in LDV biogenesis the
ablation of SgII might also impair LDV generation.
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